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Abstract
Various nonglycosylated analogs were designed in order to explore the role of glycosylation in
formaecin I, an antibacterial glycopeptide of insect origin. The functional behavior of a designed
nonglycosylated analog (P7,endo P8a,DT11)formaecin I was found to be similar to that of native
glycosylated peptide. Both the peptides showed similar antibacterial activities against Escherichia coli
and Salmonella strains. The designed nonglycosylated analog (P7,endo P8a,DT11)formaecin I has low
binding affinity to LPS identical to that of native glycopeptide, formaecin I. Both the peptides have
similar killing kinetics and are nontoxic to erythrocytes. Formaecin I and designed nonglycosylated
(P7,endo P8a,DT11)formaecin I have no definite conformational features associated with them. The
glycosylated residue of threonine in formaecin I and proline residues in designed peptide [(P7,endo
P8a,DT11)formaecin I], possibly help in stabilizing the correct conformation that facilitates presentation
of the peptide to its receptor. It is evident that a functionally equivalent nonglycosylated analog of native
glycosylated antibacterial peptide can be designed by strategically modifying the sequence.
Keywords: glycopeptide antibiotic; rational design; antibacterial activity; insect immunity
The resistance of insects to bacterial infection is explained
by their ability to synthesize a diverse range of antibacterial
peptides (Hoffmann et al. 1993; Hultmark 1993; Cociancich
et al. 1994). A remarkable feature of some proline-rich
antibacterial peptides such as drosocin, pyrrhocoricin, for-
maecins, diptericin, and lebocins that have been isolated
from insects, is the presence of a conserved glycosylated
threonine residue (Hara and Yamakawa 1995; Otvos et al.
2000a). Formaecin I consists of 16 residues, nearly one-third
of which are prolines. It is glycosylated on threonine 11 by a
monosaccharide, 2-acetamido-2-deoxy-D-galactopyranosyl
(GalNAc), and is active against Gram-negative bacteria at
concentrations in the low micromolar range. Previous
studies showed that the native glycosylated peptide, for-
maecin I, isolated from an ant, Myrmecia gulosa, had more
activity than its synthetic deglycosylated form (Mackintosh
et al. 1998). The integrity of the carbohydrate side chain is
also necessary for maximum activity of other antimicrobial
peptides such as drosocin, diptericin, and lebocins. The
exact role of the sugar remains an enigma.
Formaecin I shows significant homology at its C-terminal
end with the conserved residues of apidaecins (Casteels
et al. 1994), a class of nonglycosylated peptides isolated
from insects. Here we report designing of a nonglycosylated
analog of formaecin I that shows the antibacterial and
hemolytic activities and LPS-binding affinity similar to
the glycopeptide formaecin I, indicating that carbohydrate
function could be compensated by suitable modifications in
the peptide sequence. The study provides insight into the
possible role of glycosylation in the antibiotic activity of the
glycopeptides of innate immune origin.
Results and Discussion
Design of an active nonglycosylated formaecin I analog
Formaecin I was earlier isolated from an ant, M. gulosa
(Mackintosh et al. 1998), and belongs to the proline-rich
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class of antibacterial peptides. It has been shown that the
glycopeptide formaecin I possesses higher antibacterial
activity than its synthetically prepared deglycosylated
form. We have chemically synthesized formaecin I and
its nonglycosylated analog by using solid-phase chemistry.
The mass spectrometry analysis gave molecular masses
of 1997.43 Da and 1793.87 Da for formaecin I and its non-
glycosylated analog, respectively, in full agreement with
the theoretical values (1997.48 Da and 1794.28 Da). The
antibacterial activity of formaecin I and its deglycosylated
form against Escherichia coli BL21lD3 and Salmonella
typhimurium were determined by radial diffusion assay
(Fig. 1). The dose-dependent increase in the antibacterial
activity was evident in both cases. The chemically syn-
thesized glycopeptide formaecin I showed higher antibac-
terial activity as compared to that of the deglycosylated
peptide against different strains of Gram-negative bacteria.
This is consistent with the earlier observations (Mackintosh
et al. 1998).
The attractive features of glycopeptide antibiotics com-
pared to their nonglycosylated counterparts include
increased solubility and oral availability (Poujade et al.
1983; Fisher et al. 1991), increased serum half-life (Powell
et al. 1993), broader biological activity spectra (Biondi et al.
1993; Horvat et al. 1993), and stabilization of conforma-
tional variants (Laczko et al. 1992; Urge et al. 1992). The
present study was aimed at exploring the functional role of
glycosylation in formaecin I by designing various non-
glycosylated analogs of the glycopeptide and screening for
bioactivity. The apidaecin-type peptides (Casteels et al.
1989) are a group of nonglycosylated antibacterial peptides
of the proline-rich class and consist of conserved regions of
amino acids. The existence of conserved residues in
apidaecin (HbIb) is represented as bold letters in Figure 2.
Formaecin I can be best aligned with the apidaecin (HbIb)
isoform (Casteels et al. 1994), which is an 18-residue-long
peptide isolated from Apis mellifera (honeybee). We
observed that the glycosylated peptide formaecin I shows
a high degree of sequence homology at its C terminus to
the conserved residues of apidaecin (HbIb) (Fig. 2). The
removal of GalNAc from formaecin I resulted in (T11)
formaecin I, which showed a significant decrease in its
antibacterial activity. In order to compensate for the effect
of sugar, the nonglycosylated analogs of formaecin I with
minimal amino acid substitutions were designed on the
basis of residue conservation with the apidaecin-type
peptides. The glycosylated threonine was removed by
comparison with apidaecin (HbIb), and it resulted in the
nonglycosylated peptide (DT11)formaecin I. Apidaecin
(HbIb) contains the conserved prolines at its ninth and
eleventh positions that are not present in formaecin I. In
further designing, these prolines were incorporated sequen-
tially in the nonglycosylated analogs of formaecin I. In
(endo P8a,DT11)formaecin I, one conserved proline residue
was incorporated at the ninth position, whereas in (P7,
endo P8a,DT11)formaecin I, the asparagine at the seventh
position of nonglycosylated formaecin I was substituted
with another conserved proline residue of apidaecin (HbIb),
along with the above changes.
All these designed nonglycosylated analogs were
synthesized and assayed for their comparative spectrum
of antibacterial activities against E. coli BL21lD3
(Fig. 3). The (DT11)formaecin I peptide showed the
lowest antibacterial activity, and insertion of one proline
in (DT11)formaecin I resulted in the (endo P8a,DT11)
formaecin I peptide, which improved its antibacterial
activity to some extent. The (P7,endo P8a,DT11)formaecin
I, containing all the conserved residues of apidaecin
(HbIb), exhibited activity comparable to that of the native
formaecin I (Fig. 3). The level of antibacterial activity
was also found to be similar against the pathogenic strains
of Salmonella, that is, S. typhimurium and S. typhi Vi+
(Fig. 4) for formaecin I and the designed nonglycosylated
analog, (P7,endo P8a,DT11)formaecin I. Thus, the glyco-
peptide formaecin I and the nonglycosylated analog,
(P7,endo P8a,DT11)formaecin I, showed comparable
antibacterial activities against different Gram-negative
Figure 1. Comparison of antibacterial activity of formaecin I with its
deglycosylated form, (T11)formaecin I, against E. coli (A) and
S. typhimurium (B) expressed in terms of inhibition zone area in the radial
diffusion assay.
Figure 2. Alignment of the sequences of designed analogs of formaecin I
with reference to formaecin I and apidaecin.
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bacterial strains. Therefore, comparison was also made in
terms of other functional properties as well as structural
features between the designed active nonglycosylated
analog and native formaecin I.
Conformational analyses
Peptides are believed to adopt specific structural features
for effective binding to their putative targets. Accord-
ingly, comparative structural analysis of modified analogs
of formaecin I and glycopeptide formaecin I was carried
out by circular dichroism studies.
The conformational properties of formaecin I, (T11)
formaecin I, and (P7,endo P8a,DT11)formaecin I were ana-
lyzed by CD spectroscopy in water, 90% TFE, and 10 mM
SDS (Fig. 5). In water, all three peptides showed
the characteristics of an unordered structure (Fig. 5A).
Formaecin I and (T11)formaecin I showed a negative band
at 200 nm. In (P7,endo P8a,DT11)formaecin I, the negative
broad band was somewhat red-shifted to 203 nm, prob-
ably because of the presence of seven prolines. In 90%
aqueous trifluoroethanol, all the peptides exhibited CD
spectra similar to the pattern that has been assigned to the
presence of type I (III) b-turns or b-turn mixtures with
significant type I character and earlier reported for
drosocin and its deglycosylated form (Bulet et al. 1996).
The structure-promoting effect of TFE was apparently
less marked on formaecin I and its designed nonglycosy-
lated analog (P7,endo P8a,DT11)formaecin I. Polyproline
helices, however, exhibit a weak positive np* band
above 220 nm, whereas formaecin I and (P7,endo
P8a,DT11)formaecin I showed the broadening of the
negative band. The broadening may indicate the presence
of other types of turns, but only a low proportion of the
peptide molecules acquired them (Fig. 5B). The micellar
SDS has been used as a model of the negatively charged
bacterial lipid membranes, with which cationic peptides
first interact. In an SDS environment, all the three pep-
tides exhibited very similar CD spectra that were char-
acterized by an intense negative band at ;204 nm similar
to that observed in TFE, suggesting mainly electrostatic
peptide/micelles interaction without clear effects on the
peptide conformation (Fig. 5C). The CD studies for
formaecin I and its nonglycosylated analog (P7,endo
P8a,DT11)formaecin I in water suggested that there is no
significant difference between their secondary structures
and the presence of unordered structure in these peptides.
Indeed, the membrane-mimicking environments like TFE
and SDS did not generate any appreciably ordered
structure in both the peptides except the presence of
b-turns as exhibited by their CD spectra. Thus, conforma-
tional studies by CD have shown that the glycopeptides
formaecin I and (P7,endo P8a,DT11)formaecin I have
similar secondary structures.
Functional analyses
The designed nonglycosylated analog (P7,endo P8a,
DT11)formaecin I showed similarity with the native
glycopeptide formaecin I in terms of the antibacterial
activity profiles against different bacterial strains as well
as the structural features as observed by circular dichro-
ism spectroscopy. In order to evaluate the equivalence
of the glycopeptide and the nonglycoslylated analog, it
was pertinent to address other functional attributes as
well. Therefore, the kinetics of bacterial killing, hemo-
lytic activity, and the ability to competitively displace
Figure 3. Dose-dependent activity curves of formaecin I and its designed
nonglycosylated analogs showing antibacterial activity profiles against
E. coli. The designed nonglycosylated analog, (P7,endo P8a,DT11)formaecin
I exhibits activity comparable to that of the native formaecin I.
Figure 4. Comparison of antibacterial activity of formaecin I with
designed nonglycosylated analog, (P7,endo P8a,DT11)formaecin I against
pathogenic strains of S. typhimurium (A) and S. typhi (Vi+) (B).
Active nonglycosylated analog of formaecin I
www.proteinscience.org 311
JOBNAME: PROSCI 16#2 2007 PAGE: 3 OUTPUT: Wednesday January 3 22:27:38 2007
csh/PROSCI/127809/PS0625817
Polymyxin B from endotoxin binding were compared for
the two peptides.
The time-killing experiments were carried out to
follow the kinetics of inactivation of E. coli BL21lD3
by formaecin I, (T11)formaecin I, and (P7,endo P8a,DT11)
formaecin I and to establish whether these peptides are
bacteriostatic or bactericidal. A time-course analysis of
the inhibitory activity showed that it took an experimental
period of ;2 h for glycopeptide and (P7,endo P8a,DT11)
formaecin I at a minimum inhibitory concentration for
either peptide to completely inhibit the subsequent
growth of E. coli (Fig. 6A). After 80 min, the number
of colony-forming units had dropped to ;0% and 5% for
formaecin I and designed nonglycosylated analog
(P7,endo P8a,DT11)formaecin I, respectively. The degly-
cosylated (T11)formaecin I acts more slowly. Similar
results were found for deglycosylated drosocin (Cudic
et al. 1999). The viable cell counts were 36% after 80 min,
and all colony-forming potential disappeared only
after 4 h in the case of deglycosylated formaecin I,
(T11)formaecin I. The results show that all three peptides
are bactericidal, and the kinetics of inactivation of E. coli
is same for formaecin I and (P7,endo P8a,DT11)formaecin
I. The similar killing kinetics could be ascribed to a
similar mode of action of these peptides. It is also
supported by the fact that both of these peptides are
similar in structure. This could be further verified after
the target receptors for these antimicrobial peptides are
identified.
The effect of formaecin I and its designed analogs was
also tested on 1% (v/v) suspensions of rat erythrocytes.
When tested in a conventional hemolytic test, formaecin I
and designed nonglycosylated peptide, (P7,endo P8a,DT11)
formaecin I, and (T11)formaecin I had no hemolytic activity
on rat erythrocytes at a concentration of up to 100 mM
(data not shown). All these peptides show nontoxicity to
rat red blood cells. Thus, hemolytic activity was absent
in formaecin I as well as in (P7,endo P8a,DT11)formaecin I.
It has been suggested that in Gram-negative bacteria,
the initial interaction of these peptides with LPS occurs
through cation-binding sites on the LPS surface. The
fluorescent probe Dansyl Polymyxin B can be used to
assess the relative binding affinities of various com-
pounds to LPS. The competitive displacement of Poly-
myxin B from endotoxin by formaecin I was analyzed
and compared with the nonglycosylated analogs. It was
observed that the behavior of displacement of Polymyxin
B by formaecin I, its deglycosylated form (T11)formaecin
I, and designed nonglycosylated analog (P7,endo
P8a,DT11)formaecin I was almost similar. All these pep-
tides could displace only ;10% of the bound Polymyxin
B even at the maximum concentration of 100 mM used
(Fig. 6B). Formaecin I and its designed nonglycosylated
analog exhibited low binding affinity to LPS unlike
apidaecin, drosocin, and pyrrhocoricin. The other than
LPS molecules may be involved to facilitate the uptake of
formaecin I peptides into the cell, followed by its binding
to target molecules.
A diverse array of mechanisms by which proline-rich
antimicrobial peptides act on the bacterial cell have been
proposed. The mammalian proline-rich peptide PR-39
kills bacteria by interrupting both DNA and protein
synthesis (Skerlavaj et al. 1990), and the bactenecins
are suggested to cause loss of macromolecular synthesis
ability (Boman et al. 1993). Unlike the a-helical and most
of the cysteine-stabilized antimicrobial peptides that
kill bacteria through a nonstereospecific fashion (Bessalle
et al. 1990; Wade et al. 1990), the all-D-enantiomer of
Figure 5. Circular dichroism profiles of formaecin I, deglycosylated formaecin I [(T11)formaecin I] and designed nonglycosylated
formaecin I [(P7,endo P8a,DT11)formaecin I] in water (A), in 90% TFE (B), and in 10 mM SDS (C).
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(P7,endo P8a,DT11)formaecin I is totally ineffective against
E. coli and Salmonella strains (data not shown) similar to
apidaecin, drosocin, and pyrrhocoricin, suggesting that
these peptides are bactericidal through a mechanism that
involves a stereoselective recognition of a chiral cellular
target, most likely a protein (Casteels and Tempst 1994;
Bulet et al. 1996; Otvos et al. 2000b). Castle et al. (1999)
proposed a model of a permease/transporter-mediated
mechanism for the mode of action of apidaecin on the
Gram-negative bacterium E. coli. In an attempt to identify
the processes and molecules that might be targeted by
apidaecin after entering E. coli cells, it was shown that the
peptide rapidly blocked the protein synthesis machinery.
Otvos et al. (2000a) observed that some of the proline-rich
peptides bind to the bacterial heat-shock protein DnaK and
chaperonin GroEL. The antibacterial peptides formaecin I,
drosocin, apidaecins, and pyrrhocoricin, which exhibit
sequence similarities, are likely to have similar modes of
action.
Thus, the killing mechanism of bacteria involving
interventions at the level other than membrane, which
may include protein/nucleic acid synthesis, is evident.
Also, certain proteins/nucleic acid targets to which proline-
rich glycopeptide antibiotics bind have been identified.
However, precise description of the glycopeptide receptor
binding site is yet to be elucidated.
Conclusion
Many peptide antibiotics kill bacteria by membrane pore
formation. A characteristic property of membrane pores
involving peptide antibiotics has been suggested to be
that it is stereo nonspecific as it involves aggregation
of amphipathic a-helices (Bessalle et al. 1990; Wade
et al. 1990). However, certain antibiotic peptides such as
apidaecin, drosocin, and pyrrhocoricin have been shown
to kill bacteria in a stereospecific manner, suggesting the
possibility of alternate modes of action such as the
presence of an intracellular target biopolymer with chiral
properties (Casteels and Tempst 1994; Bulet et al. 1996;
Otvos et al. 2000b). We have found that the formaecin I
analog (P7,endo P8a,DT11)formaecin I was inactive when
made of D-amino acid residues, implying the likely mode
of action to be similar to that of apidaecin, drosocin, and
pyrrhocoricin.
If the formaecin I functions via a mechanism that
requires stereospecific recognition of a target molecule, it
must adopt a certain functional conformation, and con-
sidering that glycan moiety was shown to affect activity,
it may influence the functionally relevant conformation
of the glycopeptide antibiotic. Indeed, other biochemical
evidence exists indicating that glycosylation influences
peptide and protein structure (Rose et al. 1984; Shogren
et al. 1989; Chapman et al. 1996). It has been suggested
that peptide glycosylation influences conformation by
simply reducing the available conformational repertoire
of the otherwise flexible peptide (Andreotti and Kahne
1993; Rickert and Imperiali 1995; O’Conner and Imperiali
1998).
We have shown that the designed nonglycosylated
analog (P7,endo P8a,DT11)formaecin I could mimic the
effect of O-glycosylation in formaecin I. The (P7,endo
P8a,DT11)formaecin I, which is a nonglycoslyated analog,
shows antibacterial activity comparable to that of the
native glycopeptide. Both of these peptides have similar
functional properties such as killing kinetics and binding
affinity to LPS; the nonglycosylated (P7,endo P8a,DT11)
formaecin I must adopt conformational properties that
are similar to those of formaecin I. In other words,
the sequence modifications in this peptide may bring
about similar constraints as those by the glycan moiety.
Figure 6. Comparison of functional properties of formaecin I and
designed nonglycosylated active analog. (A) Kinetics of bactericidal
activity of formaecin I (50 mM), (T11) formaecin I (500 mM), and (P7,endo
P8a,DT11)formaecin I (50 mM), on mid-log-phase cultures of E. coli
BL21lD3 at minimum inhibitory concentration of each peptide.
(B) Competitive displacement of Dansyl Polymyxin B in a dose-dependent
manner by different peptides for endotoxin binding.
Active nonglycosylated analog of formaecin I
www.proteinscience.org 313
JOBNAME: PROSCI 16#2 2007 PAGE: 5 OUTPUT: Wednesday January 3 22:27:57 2007
csh/PROSCI/127809/PS0625817
Probably, O-linked glycosylation of threonine stabilized
the bioactive conformation of formaecin I, and the
replacement of the glycosylated-amino acid and incorpo-
ration of highly turn-forming proline residues in (P7,endo
P8a,DT11)formaecin I resulted in an unaltered conforma-
tional variant. The glycosylated threonine in formaecin
I and proline residues in designed peptide [P7,endo
P8a,DT11)formaecin I], possibly, help in stabilizing the
correct conformation that facilitates presentation of
the peptide to its stereospecific receptor. Therefore, the
designed nonglycosylated peptide could mimic the func-
tional behavior of glycosylated peptide. The high-reso-
lution conformational analysis of these peptides is needed
to specifically address the precise effect of O-linked sugar
and insertions of proline residues in the peptide.
Thus, the effect of sugar can be mimicked by making
strategically designed amino acid substitutions in the
nonglycosylated analog of glycosylated peptide. Indeed,
physiologically relevant sugar–peptide mimicry between
these two topologically similar but chemically indepen-
dent molecules has been demonstrated (Jain et al. 2000).
The reverse of this approach would also be interesting
since glycosylated peptides are much better candidates
for therapy. Indeed, such an attempt has been made by
Gobbo et al. (2002), where an extra glycosylated threo-
nine residue was inserted in the native apidaecin.
Although the resulting analog in this case exhibited lower
antibacterial activity, improved design strategies in a
variety of such systems may enable the design of effective
glycopeptide analogs of a peptide antibiotic.
Materials and methods
HMP (4-hydroxymethyl phenoxymethyl polystyrene) resin,
solvents, and reagents used for synthesis were supplied by
Applied Biosystems Inc. Fmoc amino acid derivatives were
procured from Bachem Feinchemikalein AG. Other chemicals
were purchased from Sigma Chemical Co. The Gram-negative
bacterial strains S. typhimurium, S. typhi Vi+ (clinical isolates),
and E. coli BL21(lD3) were used for the radial diffusion assay.
Agarose I (Biotechnology grade) was obtained from Amresco,
and tryptic soy broth (TSB) was from Himedia Laboratories
Pvt. Ltd.
Peptide synthesis, purification, and characterization
The Fmoc-Thr(GalNAc)-OH was synthesized by following ear-
lier reported protocols (Kuduk et al. 1998; Winans et al. 1999).
Peptides were synthesized by the solid-phase method using an
automated peptide synthesizer Model 431A (Applied Biosys-
tems Inc.), employing standard Fmoc-methodology. The pep-
tides were cleaved from the resin by treatment with TFA/
thioanisole/phenol/water/EDT in ratio as recommended by
Applied Biosystems Inc. The crude peptides were purified using
a C-18 column (Deltapak-100 A˚, 15 m, spherical, 19 3 300 mm,
Waters), and peptide purity was verified using a C-18 analytical
column (Deltapak-300 A˚, 15 m, spherical, 7.8 3 300 mm,
Waters). The sugar residue of the glycosylated peptide formae-
cin I was deacetylated by its treatment with 5% hydrazine-
hydrate and finally again purified by reverse phase column
chromatography using a C-18 column. Characterization was
performed by molecular mass determination using a single
Quadruple Mass Analyser (Fisons Instruments).
Antibacterial assays
The radial diffusion assays were performed using double-
layered agarose as described previously (Nagpal et al. 1999).
The kinetics of inactivation of the E. coli by peptides was
performed in 10% LB. Mid-log-phase bacteria (;5 3 104
colony forming units/mL) were incubated at 37°C for up to
300 min in the absence (control) or the presence of the peptides
at a concentration equal to their MIC values. Aliquots of the
suspension were withdrawn at the selected time intervals and
plated. The number of colony-forming units was counted after
24 h of incubation at 37°C.
Hemolytic assay
Hemolytic activity of the peptides was determined on freshly
isolated rat erythrocytes. Heparinized rat blood was initially
centrifuged at 3000 rpm. The erythrocyte suspension was further
washed thrice with phosphate-saline buffer (10 mM PB at
pH 7.4, 150 mM NaCl). Finally, the erythrocytes were suspended
in phosphate-buffered saline. The different concentrations of pep-
tide solutions dissolved in 250 mL of PBS were added to 250 mL
of 2% erythrocyte solution. The resulting cell suspensions in
Eppendorf tubes were incubated with the peptide in duplicate
for 30 min at 37°C with gentle mixing. The tubes were then
centrifuged, and the absorbance of the supernatants was mea-
sured at 540 nm. The hemolysis effected by only PBS and 1%
Triton X-100 was considered as zero and 100% hemolysis,
respectively.
Dansyl Polymyxin B displacement assay
Dansyl Polymyxin B, a fluorescent derivative of Polymyxin B,
was prepared by condensing Polymyxin B sulfate with dansyl
chloride as described by Schindler and Teuber (1975). The
comparative binding affinity of various antibiotic peptides for
endotoxin was investigated by a Dansyl Polymyxin B displace-
ment assay (Moore et al. 1986). The data were expressed as the
% Dansyl Polymyxin B bound to the endotoxin as a function of
peptide concentration.
Circular dichroism
The circular dichroism (CD) experiments were carried out on
a JASCO 710 spectropolarimeter with a 1.0-nm bandwidth at
0.1 nm of resolution, and 1 sec of response time using a 10-mm
pathlength cell at 25°C. Twenty to 25 scans with a speed of
200 nm/min in the range of 250–190 nm were accumulated
and averaged. The spectra were recorded at the peptide con-
centration of 10 mM in water, 10 mM phosphate buffer (pH 7),
90% trifluoroethanol, and micelles of 10 mM sodium dodecyl
sulfate in 10 mM PB (pH 7). Results were expressed as mean
residue molar ellipticity in deg cm/dmol.
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